|
|
|
 |
 |
||||||
Melior Discovery scientific advisors April 2009 Melior Discovery Newsletter Other Articles: Melior Discovery Inc (Exton, PA) has pioneered a unique, optimized, high throughput pharmacology platform that is able to systematically identify novel indications for pre-clinical and development stage drug candidates. The theraTRACE® indications discovery platform allows for known drug-like compounds to be comprehensively screened using a battery of in vivo assays spanning multiple therapeutic areas. Currently, over 35 validated animal models are represented in the platform spanning a broad range of therapeutic areas including inflammation, immunology, diabetes & metabolic syndrome, dermatology, cardiovascular, gastrointestinal, psychiatric, neurological and neurodegenerative disorders. The in vivo models utilized in the theraTRACE® platform comprise those typically used by pharmaceutical companies to determine whether a drug candidate is suitable for further clinical evaluation. However, these models are assembled in a proprietary “multiplexed” format that allows drug discoverers to evaluate a compound for potential efficacy in a broad array of therapeutic areas rapidly and cost-effectively. In most cases, Melior’s theraTRACE® system is able to provide a complete pharmacological fingerprint/profile of a compound in 10 weeks. Melior’s theraTRACE® system has found particular utility in facilitating the crucial “go/no go” development decisions routinely faced by pharmaceutical and biopharmaceutical companies. Melior’s management has combined experience of more than 120 years in pharmacology and drug discovery applications and has evaluated more than 150 compounds for novel indications in just 3 years. The company has long-term collaborations with Pfizer, Merck, AstraZeneca, Johnson and Johnson, amongst others major partners. Other articles:
|
|
